NNC0113-0987

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

DiabetesDiabetes Mellitus, Type 2Healthy

Phase 1

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

CompletedNCT01690169

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2, Healthy

Start: 2012-09-14End: 2012-12-11Updated: 2017-02-28

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

CompletedNCT01967589

Novo Nordisk A/SDiabetes, Healthy

Start: 2013-10-31End: 2014-05-31Updated: 2014-06-20

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

CompletedNCT01978613

Novo Nordisk A/SDiabetes, Healthy

Start: 2013-11-30End: 2014-06-30Updated: 2014-06-30

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

CompletedNCT02094521

Novo Nordisk A/SDiabetes, Healthy

Start: 2014-03-31End: 2014-07-31Updated: 2015-01-29